vs
ADMA BIOLOGICS, INC.（ADMA）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
BRC Group Holdings, Inc.的季度营收约是ADMA BIOLOGICS, INC.的1.4倍（$188.3M vs $139.2M），BRC Group Holdings, Inc.净利率更高（47.9% vs 35.5%，领先12.5%），ADMA BIOLOGICS, INC.同比增速更快（18.4% vs -21.9%），过去两年ADMA BIOLOGICS, INC.的营收复合增速更高（30.4% vs -15.4%）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
ADMA vs RILY — 直观对比
营收规模更大
RILY
是对方的1.4倍
$139.2M
营收增速更快
ADMA
高出40.2%
-21.9%
净利率更高
RILY
高出12.5%
35.5%
两年增速更快
ADMA
近两年复合增速
-15.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $188.3M |
| 净利润 | $49.4M | $90.3M |
| 毛利率 | 63.8% | 79.5% |
| 营业利润率 | 45.1% | 32.3% |
| 净利率 | 35.5% | 47.9% |
| 营收同比 | 18.4% | -21.9% |
| 净利润同比 | -55.9% | 1710.8% |
| 每股收益（稀释后） | $0.20 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADMARILY
| Q4 25 | $139.2M | $188.3M | ||
| Q3 25 | $134.2M | $215.3M | ||
| Q2 25 | $122.0M | $188.2M | ||
| Q1 25 | $114.8M | $197.2M | ||
| Q4 24 | $117.5M | $241.0M | ||
| Q3 24 | $119.8M | $225.5M | ||
| Q2 24 | $107.2M | $256.0M | ||
| Q1 24 | $81.9M | $263.4M |
净利润ADMARILY
| Q4 25 | $49.4M | $90.3M | ||
| Q3 25 | $36.4M | $91.1M | ||
| Q2 25 | $34.2M | $139.5M | ||
| Q1 25 | $26.9M | $-10.0M | ||
| Q4 24 | $111.9M | $-5.6M | ||
| Q3 24 | $35.9M | $-284.4M | ||
| Q2 24 | $32.1M | $-433.6M | ||
| Q1 24 | $17.8M | $-49.2M |
毛利率ADMARILY
| Q4 25 | 63.8% | 79.5% | ||
| Q3 25 | 56.3% | 83.7% | ||
| Q2 25 | 55.1% | 81.3% | ||
| Q1 25 | 53.2% | 81.4% | ||
| Q4 24 | 53.9% | 79.8% | ||
| Q3 24 | 49.8% | 82.1% | ||
| Q2 24 | 53.6% | 84.5% | ||
| Q1 24 | 47.8% | 85.3% |
营业利润率ADMARILY
| Q4 25 | 45.1% | 32.3% | ||
| Q3 25 | 38.0% | 30.4% | ||
| Q2 25 | 35.1% | 5.7% | ||
| Q1 25 | 30.4% | -31.2% | ||
| Q4 24 | 32.6% | -69.2% | ||
| Q3 24 | 33.1% | -36.4% | ||
| Q2 24 | 36.6% | -90.8% | ||
| Q1 24 | 26.7% | -6.1% |
净利率ADMARILY
| Q4 25 | 35.5% | 47.9% | ||
| Q3 25 | 27.1% | 42.3% | ||
| Q2 25 | 28.1% | 74.1% | ||
| Q1 25 | 23.4% | -5.1% | ||
| Q4 24 | 95.2% | -2.3% | ||
| Q3 24 | 30.0% | -126.1% | ||
| Q2 24 | 29.9% | -169.4% | ||
| Q1 24 | 21.7% | -18.7% |
每股收益（稀释后）ADMARILY
| Q4 25 | $0.20 | $2.78 | ||
| Q3 25 | $0.15 | $2.91 | ||
| Q2 25 | $0.14 | $4.50 | ||
| Q1 25 | $0.11 | $-0.39 | ||
| Q4 24 | $0.45 | $-0.01 | ||
| Q3 24 | $0.15 | $-9.39 | ||
| Q2 24 | $0.13 | $-14.35 | ||
| Q1 24 | $0.08 | $-1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | $226.6M |
| 总债务越低越好 | $72.1M | $1.4B |
| 股东权益账面价值 | $477.3M | $-171.5M |
| 总资产 | $624.2M | $1.7B |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资ADMARILY
| Q4 25 | $87.6M | $226.6M | ||
| Q3 25 | $61.4M | $184.2M | ||
| Q2 25 | $90.3M | $267.4M | ||
| Q1 25 | $71.6M | $138.3M | ||
| Q4 24 | $103.1M | $146.9M | ||
| Q3 24 | $86.7M | $159.2M | ||
| Q2 24 | $88.2M | $236.9M | ||
| Q1 24 | $45.3M | $190.7M |
总债务ADMARILY
| Q4 25 | $72.1M | $1.4B | ||
| Q3 25 | $72.4M | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | $72.3M | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ADMARILY
| Q4 25 | $477.3M | $-171.5M | ||
| Q3 25 | $431.2M | $-260.5M | ||
| Q2 25 | $398.3M | $-351.7M | ||
| Q1 25 | $373.4M | $-496.8M | ||
| Q4 24 | $349.0M | $-488.2M | ||
| Q3 24 | $231.9M | $-497.6M | ||
| Q2 24 | $188.3M | $-218.3M | ||
| Q1 24 | $153.7M | $228.4M |
总资产ADMARILY
| Q4 25 | $624.2M | $1.7B | ||
| Q3 25 | $568.7M | $1.7B | ||
| Q2 25 | $558.4M | $1.5B | ||
| Q1 25 | $510.6M | $1.5B | ||
| Q4 24 | $488.7M | $1.8B | ||
| Q3 24 | $390.6M | $2.2B | ||
| Q2 24 | $376.4M | $3.2B | ||
| Q1 24 | $350.9M | $5.0B |
负债/权益比ADMARILY
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $34.6M | — |
| 自由现金流率自由现金流/营收 | 24.8% | — |
| 资本支出强度资本支出/营收 | 0.8% | — |
| 现金转化率经营现金流/净利润 | 0.72× | 0.29× |
| 过去12个月自由现金流最近4个季度 | $27.8M | — |
8季度趋势，按日历期对齐
经营现金流ADMARILY
| Q4 25 | $35.6M | $26.2M | ||
| Q3 25 | $13.3M | $-60.6M | ||
| Q2 25 | $21.1M | $-25.6M | ||
| Q1 25 | $-19.7M | $184.0K | ||
| Q4 24 | $50.2M | $-2.7M | ||
| Q3 24 | $25.0M | $19.5M | ||
| Q2 24 | $45.6M | $111.5M | ||
| Q1 24 | $-2.2M | $135.4M |
自由现金流ADMARILY
| Q4 25 | $34.6M | — | ||
| Q3 25 | $-1.1M | — | ||
| Q2 25 | $18.7M | — | ||
| Q1 25 | $-24.4M | — | ||
| Q4 24 | $47.5M | — | ||
| Q3 24 | $24.0M | — | ||
| Q2 24 | $43.6M | — | ||
| Q1 24 | $-4.6M | — |
自由现金流率ADMARILY
| Q4 25 | 24.8% | — | ||
| Q3 25 | -0.8% | — | ||
| Q2 25 | 15.3% | — | ||
| Q1 25 | -21.2% | — | ||
| Q4 24 | 40.4% | — | ||
| Q3 24 | 20.0% | — | ||
| Q2 24 | 40.7% | — | ||
| Q1 24 | -5.6% | — |
资本支出强度ADMARILY
| Q4 25 | 0.8% | — | ||
| Q3 25 | 10.7% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 4.1% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | 1.9% | — | ||
| Q1 24 | 2.9% | — |
现金转化率ADMARILY
| Q4 25 | 0.72× | 0.29× | ||
| Q3 25 | 0.36× | -0.66× | ||
| Q2 25 | 0.62× | -0.18× | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
